Figure 5.

Secretion of cf-mtDNA and influence of biologic DMARDs on cf-mtDNA levels. (A) cf-mtDNA levels secreted from synovial cells at various confluencies. Results were expressed as the mean ± SEM.; n = 3. (B) cf-mtDNA levels in plasma of RA patients incubated with tocilizumab (TCZ), etanercept (ETN), adalimumab (ADA), certolizumab (CZP), or golimumab (GLM). (C) cf-mtDNA levels in plasma of RA patients incubated with TCZ, ADA, or GLM after 60 min. (B, C) Results are mean ± SEM (Wilcoxon signed-rank test); n = 5; *P < 0.05; n.s.: not significant